Results 121 to 130 of about 14,887 (173)

Longitudinal management and novel pharmacological interactions in a patient with HeFH, 21-OHD, and kawasaki disease: a 6-year clinical follow-up. [PDF]

Front Endocrinol (Lausanne)
Zhang Y, Yuan X, Yang X, Chen R.
europepmc   +1 more source

Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition and Cancer Risk: Insights from a Large Propensity-Matched Cohort Study. [PDF]

Clin Pharmacol Ther
Nardi Agmon I, Gurevitz C, Shochat T, Kushnir S, Witberg G, Levi A, Gilon D, Kornowski R, Thavendiranathan P, Abdel Qadir H, Iakobishvili Z.   +10 more
europepmc   +1 more source

Impact of Age on Lipid-Lowering Therapy Prescriptions and LDL-Cholesterol Control: Insights from the PORTRAIT-DYS Study. [PDF]

Glob Heart
Gavina C, Seabra D, Oliveira S, Teixeira C, Ruivo JA, Lourenço-Silva N, Luz AR, Jácome C, Araújo F.   +8 more
europepmc   +1 more source

Physician Disagreement With Guidelines as a Critical Barrier to Achieving LDL-C Targets in Very High-Risk Patients: An Implementation Science Study. [PDF]

J Korean Med Sci
Cho KH, Cho YR, Lee SR, Bae JW, Nam CW, Park Y, Hwang JY, Yun KH, Kim W, Kim MC, Sim DS, Hong YJ, Kim JH, Ahn Y, Hahn JY, Jeong MH.   +15 more
europepmc   +1 more source

Pharmacokinetic comparison of ezetimibe/rosuvastatin/telmisartan 10/20/80 mg fixed-dose combination versus coadministration of separate tablets in healthy participants. [PDF]

Naunyn Schmiedebergs Arch Pharmacol
Goh S, Huh KY, Lee S, Cho JY, Yu KS.
europepmc   +1 more source

Combination Lipid-Lowering Therapy After ACS: Should this be the New Standard of Care? [PDF]

Curr Cardiol Rep
Brandts J, Marx N.
europepmc   +1 more source